Markets:

Overview

News

Currencies

International

Treasuries

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

31.38 +0.15 (+0.48%)

Official Closing Price Updated: 7:00 PM EST, Jan 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Hims & Hers Health, Inc. Class A Common Stock

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

48 49 Next >

Charter Communications To Rally Around 20%? Here Are 10 Top Analyst Forecasts For Tuesday ↗

November 05, 2024

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

November 05, 2024

Via Benzinga

Palantir, Trump Media, Hims & Hers Health, NXP Semiconductors, And Tesla: Why These 5 Stocks Are On Investors' Radars Today ↗

November 04, 2024

The U.S. stock market experienced a slight downturn on Monday, with the S&P 500 index dipping approximately 0.3%. The Dow Jones Industrial Average fell 0.6% to 41,794.60.

Via Benzinga

Topics Government Stocks

Hims & Hers Health Reports Better-Than-Expected Q3 Results: Details ↗

November 04, 2024

Hims & Hers Health reported its third-quarter results after Monday's closing bell. Here's a look at the details from the report.

Via Benzinga

Decoding Hims & Hers Health's Options Activity: What's the Big Picture? ↗

November 04, 2024

Via Benzinga

Smart Money Is Betting Big In HIMS Options ↗

October 30, 2024

Via Benzinga

A Look Into Hims & Hers Health Inc's Price Over Earnings ↗

October 22, 2024

Via Benzinga

How Is The Market Feeling About Hims & Hers Health? ↗

October 22, 2024

Via Benzinga

IBD 50's No. 2 Stock, Hims & Hers, Smashes Estimates On 'Robust' Obesity Trajectory ↗

November 04, 2024

Hims stock jumped late Monday after the online pharmacy beat expectations.

Via Investor's Business Daily

Hims & Hers Health, Inc. Reports Third Quarter 2024 Financial Results

November 04, 2024

From Hims & Hers

Via Business Wire

What's Going On With Hims & Hers Health Stock Monday? ↗

November 04, 2024

Hims & Hers Health will report third-quarter financial results after the market close on Monday. Analysts expect the company to report earnings of 4 cents per share and revenue of $382.2 million,...

Via Benzinga

Hims & Hers Health Stock Is Trading Lower Wednesday: Here's Why ↗

October 30, 2024

Hims & Hers Health shares are falling Thursday following an FDA update listing Novo Nordisk diabetes drug Ozempic and weight-loss drug Wegovy as available, signaling possible supply stability. Here's...

Via Benzinga

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

October 30, 2024

Via Benzinga

This Is What Whales Are Betting On Hims & Hers Health ↗

October 21, 2024

Via Benzinga

Decoding 6 Analyst Evaluations For Hims & Hers Health ↗

October 21, 2024

Via Benzinga

Could This Magnificent Pharma Stock 10x in the Next 5 Years? ↗

October 30, 2024

Disrupting pharmacies is just the start for Hims & Hers.

Via The Motley Fool

How Compounded Treatments Are Helping Hims & Hers Customers Meet Their Weight Loss Goals

October 29, 2024

From Hims & Hers

Via Business Wire

Top 3 Stocks Institutions Are Buying Right Now

October 28, 2024

Despite the stock market trading at new all-time highs, institutions still find enough reason to buy more enormous stakes in three stocks.

Via MarketBeat

Hims & Hers Stock Dropped: Here's What You Need to Know ↗

October 24, 2024

The GLP-1 drama continues at Hims & Hers.

Via The Motley Fool

In-Depth Examination Of 6 Analyst Recommendations For Hims & Hers Health ↗

October 21, 2024

Via Benzinga

Ozempic And Wegovy Maker Novo Nordisk Asks FDA To Halt Production Of Compounded Fat Loss Drugs Due To Their 'Inherent Complexity' ↗

October 23, 2024

Via Benzinga

Hims & Hers names Dr. Jessica Shepherd as Chief Medical Officer of Hers

October 21, 2024

From Hims & Hers

Via Business Wire

Why Hims & Hers' Incredible Growth Will Continue ↗

October 18, 2024

GLP-1s get all the attention, but Hims & Hers' core business is where the rocket growth is.

Via The Motley Fool

Hims & Hers Shares Have Rallied 22% This Week. Why That Move Is Now At Risk. ↗

October 16, 2024

Hims & Hers has enjoyed a rally on an FDA decision regarding Eli Lilly's tirzepatide.

Via Investor's Business Daily

Hims & Hers to Announce Third Quarter 2024 Financial Results on November 4, 2024

October 14, 2024

From Hims & Hers

Via Business Wire

Hims & Hers Health Stock Is Popping Monday: What's Behind The Move? ↗

October 14, 2024

Hims & Hers Health Inc (NYSE:HIMS) shares are trading higher Monday after the U.S. Food and Drug Administration said it would reconsider a decision barring drug compounders from selling their own...

Via Benzinga

Hims & Hers Health Pops After FDA Allows Compounded Copies Of Eli Lilly's Obesity Drug ↗

October 14, 2024

An industry group sued the FDA, claiming tirzepatide remains in shortage.

Via Investor's Business Daily

Topics Lawsuit

Where Does Hims & Hers Stock Go From Here? ↗

October 12, 2024

Is Hims & Hers in trouble since the FDA put a time clock on some GLP-1s, or is the future still bright?

Via The Motley Fool

2 Incredibly Cheap Growth Stocks to Buy Right Now ↗

October 12, 2024

Look beyond the stock price at the business when shares are volatile.

Via The Motley Fool

2 No-Brainer Growth Stocks to Buy With $500 Right Now ↗

October 12, 2024

Consistently investing even moderate sums can grow your portfolio with time.

Via The Motley Fool

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

48 49 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Hims & Hers Health, Inc. Class A Common Stock (NY:HIMS)

All News about Hims & Hers Health, Inc. Class A Common Stock

Starting at $3.75/week.

Subscribe Today